InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by Seymour Albert, Directeur Scientifique. Officer active across 1 company, notably Homology Medicines, Inc.. Cumulatively, 4 filings have been published. Split: 0 buy · 1 sell. Total volume traded: €5k. History available since 9 January 2023. The latest transaction was disclosed on 9 January 2023 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Seymour Albert
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
4,620 sharesCommon StockSEC:0000950170-23-047302:0
3,620 shares@ US$1.3904100.0% of flowCommon StockSEC:0000899243-23-001575:0
4,290 sharesCommon StockSEC:0000899243-23-000629:0
4,290 sharesCommon StockSEC:0000899243-22-001746:0
4 of 4 declarations
About Seymour Albert
Seymour Albert is the Chief Scientific Officer at Homology Medicines, Inc. In this role, he is responsible for leading the scientific initiatives and research within the company. His expertise contributes to the advancement of innovative technologies and treatments developed by the firm. Seymour plays a key role in the research and development strategy, aiming to improve patient outcomes through cutting-edge therapeutic solutions.
